Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Melanoma/Skin Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicenter retrospective analysis of nivolumab in advanced melanoma during the French Temporary Authorization Use.

Sandrine Monestier

e21598

A multi-gene risk signature for improved identification of cutaneous squamous cell carcinoma (cSCC) patients with a high risk of recurrence.

Chrysalyne Schmults

9577

A prognostic gene-signature based identification of high-risk thin melanomas.

Peter Koelblinger

e21575

Adjuvant therapy utilization among stage III melanoma patients.

C. Lance Cowey

e21574

Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.

Todd Wechter

e21568

Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.

Geoffrey Thomas Gibney

e21609

Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.

Daan Hurkmans

9579

Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.

Yesung Lee

e21585

BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis.

Lars Ny

e21566

Co-isolation and analysis of extracellular vesicle (EV)-associated DNA and cell free DNA (cfDNA) to improve the diagnostic and prognostic value of circulating BRAF V600E in metastatic melanoma patients.

Davide Zocco

e21564

Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.

Nicolas Girard

9587

Cytokeratin 19 expression as a risk factor for metastasis in cutaneous squamous cell carcinoma.

Hisashi Uhara

e21603

Dissecting genetic heterogeneity in stage III cutaneous malignant melanoma with spatially resolved transcriptomics.

Hanna Eriksson

e21587

Does aggressive treatment in pediatric melanoma improve survival? A comparison of melanoma treatment and prognosis by age.

Alicia Gingrich

e21563

Effect of a delay in definitive surgery in melanoma on overall survival: A NCDB analysis.

Alina Basnet

e21586

Emergent renal and hepatic dysfunction (dys) in a real-world cohort of advanced melanoma (aMel) patients (pts) receiving first line (1L) immune checkpoint inhibitors (ICIs).

Susan Spillane

e21582

Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from the peripheral blood of a melanoma patient following successful treatment with immune checkpoint blockade.

Mark R. Albertini

e21607

Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma.

Alvaro Moreira

e21573

Epidemiological study of unknown primary melanoma patients from the French national melanoma database RIC-Mel.

Emilie Varey

e21571

External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III.

Max Fullah Madu

9500

Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma.

Jiayi Yu

9588

Gut microbiome and immunotherapy response in melanoma patients.

Brandilyn Peters

9575

Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.

Elisa A. Rozeman

9585

Immune-related adverse events (IRAE) of elderly patients (PTS) with advanced melanoma (AMEL) treated with checkpoint inhibitors (CI) in a community setting: The experience (EXP) at Kaiser Permanente (KP) California.

Thach-Giao Truong

e21583

Impact of a gene expression profiling risk score and web-based melanoma outcome calculator on the precision of AJCC-based prognostic assessment.

Georg Brunner

9582

Implications of melanoma with diabetes mellitus on patient outcomes.

Nina J. Karlin

e21595

INPP5a expression as a prognostic marker in cutaneous squamous cell carcinoma (cSCC).

Helen J Liang

e21567

Matrix metalloproteinase as a prognostic marker of malignancy in melanocytic tumors.

Elena Petrovna Ulianova

e21597

Merkel cell carcinoma in Turkey: A multicentric study.

Fatih Yildiz

e21591

Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma.

Lee S. Gottesdiener

e21579

Mutation burden in conjunction with MAPK-pathway mutation status as a prognostic biomarker of overall melanoma survival.

John Cadley

9584

Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

Reinhard Dummer

9574

Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma.

Aleksi Emil Suo

e21577

Performance of a 31-gene expression profile melanoma test in clinically relevant clinicopathologic subgroups.

Brian Gastman

9583

Peripheral blood T-cell functional assay as a predictive biomarker of immune-therapy of metastatic melanoma.

Harsh V Parmar

e21593

Persistent high levels of circulating effector memory T cells and anti-nuclear antibodies in metastatic melanoma patients who experience durable CRs to immunotherapy after the cessation of treatment.

Megan Wheelden

e21576

Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.

David Liu

9581

Predictive plasma proteomic biomarkers of immunotherapy toxicity in patients (pts) with metastatic melanoma (MM).

Meghan Mooradian

e21569

Prognostic differences between male and female patients in virus-negative Merkel cell carcinoma.

Lisa Villabona

e21601

Prognostic role of BRAF mutation in malignant cutaneous melanoma.

Amikar Sehdev

e21599

Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma.

Robyn Denise Gartrell

9580

Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.

Claire-Audrey Bayan

e21600

Recurrence of eyelid tumor after Mohs vs. frozen sections.

Alice Song

e21594

Skin test results with common and melanoma antigens in metastatic melanoma patients being treated with intratumoral injections.

Max H. Cohen

e21602

Surveillance for melanoma (MEL): Results of a database study of stage I-III MEL.

Corey Rearick

9586

T-cell biological aging in melanoma: Impact on immunotherapeutic discontinuation.

Christin Elizabeth Burd

e21578

The clinical characteristic of V600R-mutant melanoma: A single institution experience.

Karen Malkhasyan

e21581

The prevalence of Merkel cell polyomavirus in Russian patients with Merkel cell carcinoma.

Kristina V. Orlova

e21605

The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.

Simone M. Goldinger

e21588

Time to treatment failure (TTF) as a potential clinical endpoint in real-world evidence (RWE) studies of melanoma.

Rajeshwari Sridhara

9578

Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.

Tuba Nur Gide

9518

Using deep learning algorithms on histopathology images for the prediction of BRAF and NRAS mutations in invasive melanoma.

Randie H Kim

e21561

Using real world data to evaluate overall survival in PD1-treated vs. standard of care metastatic melanoma patients.

Purvi Dev-Vartak

e21606

Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.

Margaret Borgardus

9576